+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 50Years - 80Years
All Genders
Healthy Volunteers
ID06907589

A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective Early Diagnosis and Therapeutic Monitoring of Parkinsons Disease Promoting Continuity of Care

Led by Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna · Updated on 2025-04-02

250

Participants Needed

5

Research Sites

1 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the SensMode System, a set of wearable devices designed to analyze upper and lower limb movements. This study involves healthy adults, subjects with idiopathic hyposmia, patients with Parkinsons disease, and individuals with newly diagnosed drug-nafve extrapyramidal syndrome. The goal is to establish normal ranges for objective motor measurements and explore how this technology might aid in early diagnosis and management of Parkinsons disease. Participants will use the SensMode System, which includes SensHand and SensFoot devices. SensHand consists of sensorized rings and a wristband that measure movement and orientation of the hand and forearm, while SensFoot is a device placed over the shoe to assess lower limb motion. All subjects undergo motor analysis using these sensors at enrollment. During the study, researchers will monitor various motor outcome measures such as the number of repetitions of specific movements, time to stand up, gait time, rotation time, fundamental frequencies from accelerometer signals, and stride count at enrollment. This data will help characterize motor function and support further research into Parkinsons disease diagnosis and care. The study runs from May 2024 to January 2026 and includes adults aged 50 to 80 years.

CONDITIONS

Brief Title

A Novel Accessible and Widespread Healthcare Service Model Based on Technology Innovation for Objective (Early) Diagnosis and Therapeutic Monitoring of Parkinson's Disease Promoting Continuity of Care

Who Can Participate

Age: 50Years - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult subjects, both sexes, aged 50-80 years old
  • MMSE score of 24 or higher
  • For healthy subjects: no olfactory deficit as measured by IOIT olfactory test with age-specific normal scores
  • No neurological diseases
  • No functional deficits in locomotion due to injury or other causes affecting limbs, pelvis, or spine
  • Informed consent to participate in the study
  • For Parkinson's disease subjects: diagnosis of Parkinson's disease without severe motor fluctuations or dyskinesias
  • Hoehn and Yahr stage 1, 2, or 3
  • Examined in the ON phase and absence of dyskinesias
  • Informed consent to participate in the study
Not Eligible

You will not qualify if you...

  • Denial of informed consent
  • Olfactory deficit detected on IOIT olfactory test above age-specific hyposmia thresholds for healthy subjects
  • Body weight greater than 120 kg
  • Insufficient cooperation
  • Active malignant neoplasm or negative follow-up less than 6 years
  • Structured joint stiffness preventing movement execution
  • Paresis or plegia of upper or lower limbs from nerve injury
  • Sensory and/or motor neuropathy
  • Chronic inflammatory joint diseases
  • Acute vertiginous syndromes
  • Neurodegenerative diseases other than Parkinson's disease
  • Fever
  • Venous thrombosis
  • Cardiovascular or other acute or chronic conditions affecting motor exercise performance
  • Spinal or joint pain affecting motor exercises
  • History of recurrent acute cervico-brachialgia or low back pain
  • For Parkinson's disease subjects: Hoehn and Yahr stage 4 or 5
  • Need for walking aid or inability to walk without assistance

Research Team

F

Filippo Cavallo

E

Erika Rovini

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here